Armata Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ARMP$3.75-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
Three Months Ended March 31, 2025 and 2024
(in thousands, except share data)
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Stockholders’ Deficit | ||||||||||||||
| · · Common Stock · · · · · · · · · | ||||||||||||||
| · · · · · · · Additional · · · · Total | ||||||||||||||
| · · · · · · · Paid-in · · Accumulated · · Stockholders’ | ||||||||||||||
| · Shares · Amount · Capital · Deficit · Deficit | ||||||||||||||
| Balances, December 31, 2023 | 36,122,932 | | $361 | | $276,393 | | $(308,819) | | $(32,065) | |||||
| Exercise of stock options | | 13,407 | | | — | | | 42 | | | — | | | 42 |
| Withholdings for taxes related to net share settlement of equity awards | | (4,222) | | | — | | | — | | | — | | | — |
| Stock-based compensation expense | — | | | — | | | 534 | | | — | | | 534 | |
| Net loss | — | | | — | | | — | | | (25,021) | | | (25,021) | |
| Balances, March 31, 2024 | 36,132,117 | | $361 | | $276,969 | | $(333,840) | | $(56,510) | |||||
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | Stockholders’ Deficit | ||||||||||||
| | | Common Stock | | | | | | | | | | |||
| | | | | | | | Additional | | | | Total | |||
| | | | | | | | Paid-in | | Accumulated | | Stockholders’ | |||
| | Shares | Amount | Capital | Deficit | Deficit | |||||||||
| Balances, December 31, 2024 | 36,183,067 | | $362 | | $279,354 | | $(327,735) | | $(48,019) | |||||
| Issuance of Common Stock upon release of restricted stock units, net of tax withholdings | | 10,412 | | | — | | | (14) | | | — | | | (14) |
| Stock-based compensation expense | — | | | — | | | 781 | | | — | | | 781 | |
| Net loss | — | | | — | | | — | | | (6,531) | | | (6,531) | |
| Balances, March 31, 2025 | 36,193,479 | | $362 | | $280,121 | | $(334,266) | | $(53,783) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.